JP5252585B2 - 代謝障害の治療のための化合物 - Google Patents

代謝障害の治療のための化合物 Download PDF

Info

Publication number
JP5252585B2
JP5252585B2 JP2009514546A JP2009514546A JP5252585B2 JP 5252585 B2 JP5252585 B2 JP 5252585B2 JP 2009514546 A JP2009514546 A JP 2009514546A JP 2009514546 A JP2009514546 A JP 2009514546A JP 5252585 B2 JP5252585 B2 JP 5252585B2
Authority
JP
Japan
Prior art keywords
diabetes
composition
group
obesity
insulin resistance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2009514546A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009539877A5 (enExample
JP2009539877A (ja
Inventor
シャリニ シャルマ，
ボーステル， レイド ダブリュー． フォン
Original Assignee
ウェルスタット セラピューティクス コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ウェルスタット セラピューティクス コーポレイション filed Critical ウェルスタット セラピューティクス コーポレイション
Publication of JP2009539877A publication Critical patent/JP2009539877A/ja
Publication of JP2009539877A5 publication Critical patent/JP2009539877A5/ja
Application granted granted Critical
Publication of JP5252585B2 publication Critical patent/JP5252585B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2009514546A 2006-06-09 2007-06-08 代謝障害の治療のための化合物 Expired - Fee Related JP5252585B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80433606P 2006-06-09 2006-06-09
US60/804,336 2006-06-09
PCT/US2007/070691 WO2007146768A2 (en) 2006-06-09 2007-06-08 Compounds for the treatment of metabolic disorders

Publications (3)

Publication Number Publication Date
JP2009539877A JP2009539877A (ja) 2009-11-19
JP2009539877A5 JP2009539877A5 (enExample) 2011-07-21
JP5252585B2 true JP5252585B2 (ja) 2013-07-31

Family

ID=38832700

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009514546A Expired - Fee Related JP5252585B2 (ja) 2006-06-09 2007-06-08 代謝障害の治療のための化合物

Country Status (12)

Country Link
US (1) US20100234464A1 (enExample)
EP (1) EP2026659A4 (enExample)
JP (1) JP5252585B2 (enExample)
KR (1) KR101391905B1 (enExample)
CN (1) CN101466266A (enExample)
AU (1) AU2007257854B2 (enExample)
CA (1) CA2654530A1 (enExample)
IL (1) IL195392A0 (enExample)
MX (1) MX2008015640A (enExample)
NZ (1) NZ573031A (enExample)
WO (1) WO2007146768A2 (enExample)
ZA (1) ZA200809774B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024005144A1 (ja) 2022-07-01 2024-01-04 国立大学法人東京大学 体表面潰瘍治癒促進装置

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090176885A1 (en) * 2006-02-02 2009-07-09 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
EP2240024A4 (en) * 2008-01-15 2014-05-21 Wellstat Therapeutics Corp COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
CA2716860C (en) 2008-03-13 2017-08-29 Wellstat Therapeutics Corporation Compounds and method for reducing uric acid
RU2573933C1 (ru) 2014-08-21 2016-01-27 Дафот Энтерпрайсис Лимитед Пептид для лечения сахарного диабета 2-го типа и его осложнений

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60123665T2 (de) * 2000-12-26 2007-08-16 Sankyo Co., Ltd. Medizinische zusammensetzungen mit diuretischem und die insulinresistenz verbesserndem mittel
CN100344616C (zh) * 2001-06-12 2007-10-24 维尔斯达医疗公司 用于治疗代谢失调的化合物
AU2003286728A1 (en) * 2002-11-01 2004-06-07 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
KR101106631B1 (ko) * 2003-02-13 2012-01-20 웰스태트 테러퓨틱스 코포레이션 대사 질환의 치료용 화합물
PL1633340T3 (pl) * 2003-04-15 2011-04-29 Wellstat Therapeutics Corp Związki do leczenia chorób metabolicznych
CA2521589C (en) * 2003-04-22 2011-11-01 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
KR101192272B1 (ko) * 2003-04-30 2012-10-17 웰스태트 테러퓨틱스 코포레이션 대사 질환의 치료용 화합물
WO2005018628A1 (en) * 2003-08-20 2005-03-03 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
JP2009531280A (ja) * 2006-01-25 2009-09-03 ウェルスタット セラピューティクス コーポレイション 代謝障害を処置するための化合物
EP1976378A4 (en) * 2006-01-25 2010-06-09 Wellstat Therapeutics Corp COMPOUNDS FOR THE TREATMENT OF METABOLISM DISORDER

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024005144A1 (ja) 2022-07-01 2024-01-04 国立大学法人東京大学 体表面潰瘍治癒促進装置

Also Published As

Publication number Publication date
CN101466266A (zh) 2009-06-24
ZA200809774B (en) 2010-10-27
WO2007146768A3 (en) 2008-02-21
IL195392A0 (en) 2009-08-03
WO2007146768A2 (en) 2007-12-21
AU2007257854A1 (en) 2007-12-21
AU2007257854B2 (en) 2012-04-12
JP2009539877A (ja) 2009-11-19
EP2026659A2 (en) 2009-02-25
NZ573031A (en) 2011-11-25
KR101391905B1 (ko) 2014-05-07
KR20090018795A (ko) 2009-02-23
US20100234464A1 (en) 2010-09-16
EP2026659A4 (en) 2010-06-30
MX2008015640A (es) 2009-01-09
CA2654530A1 (en) 2007-12-21

Similar Documents

Publication Publication Date Title
JP5371062B2 (ja) 代謝障害の処置のための化合物
US8044243B2 (en) Compounds for the treatment of metabolic disorders
JP2009537559A (ja) 代謝障害の処置のための化合物
JP2009531288A5 (enExample)
JP4837557B2 (ja) 代謝障害の処置のための化合物
US7645772B2 (en) Treatment of metabolic disorders
JP4697973B2 (ja) 代謝障害の処置のための化合物
JP2009531280A (ja) 代謝障害を処置するための化合物
JP5240927B2 (ja) 代謝障害の処置のための化合物
JP2006517920A (ja) 代謝性障害の処置のための化合物
JP4703563B2 (ja) 代謝障害を治療するための化合物
JP2006507303A5 (enExample)
JP5252585B2 (ja) 代謝障害の治療のための化合物
JP5496913B2 (ja) 代謝異常の治療のための化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100513

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110502

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120820

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121119

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121127

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121219

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121227

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130117

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130131

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130131

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130410

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130411

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20160426

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees